AMBRX BIOPHARMA INC-ADR (AMAM)
US02290A1025 - ADR
AMBRX BIOPHARMA INC-ADR
NASDAQ:AMAM (9/28/2023, 7:00:00 PM)
After market: 11.2 0 (0%)11.2
+0.3 (+2.75%)
Company Profile
Ambrx Biopharma Inc. operates as a clinical-stage biologics company. The company is headquartered in La Jolla, California and currently employs 66 full-time employees. The company went IPO on 2021-06-18. The company is focused on discovering and developing a novel class of engineered precision biologics, using its expanded genetic code technology platform that allows it to incorporate, in a site-specific manner, synthetic amino acids (SAAs), into proteins within living cells. Its product candidates are designed to overcome the inherent limitations of conventional conjugation approaches that use natural amino acids for non-site-specific conjugation, offering potential safety and benefits to treat patients across multiple therapeutic areas. Its SAA incorporation technology is designed to develop a range of product candidate modality, such as antibody-drug conjugates (ADCs), immuno-oncology conjugate, bispecific antibodies, PEGylated peptides, modified cytokines and immuno-stimulating antibody conjugates. Its lead ADC product candidates in clinical development: ARX788 and ARX517. ARX517 is an anti-prostate-specific membrane antigen.
Company Info
AMBRX BIOPHARMA INC-ADR
10975 North Torrey Pines Road
La Jolla CALIFORNIA
P: 18588752400.0
CEO: Feng Tian
Employees: 66
Website: https://ambrx.com/
AMAM News
In-person event and virtual webcast to be held on Sunday, October 22, 2023 at 8:00pm CEST / 2:00pm ET...
7 days ago - The Motley FoolWhy Shares of Ambrx Biopharma Soared This WeekA big buy by an asset manager spurred interest in the biotech stock.
9 days ago - Seeking AlphaAmbrx Biopharma says Cormorant Asset Management buys 2.15M shares (NASDAQ:AMAM)Ambrx Biopharma (AMAM) disclosed on Sept. 19 that Coronation Asset Management purchased 2.15M shares in the company from a period between Sept.15 to 18. The shares were purchased at a...
13 days ago - Market News VideoAmbrx Biopharma (AMAM) Shares Cross Below 200 DMASAN DIEGO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., Ambrx (or the “Company”) (NASDAQ: AMAM), today announced that Daniel J. O’Connor,...
a month ago - Investor's Business DailyAmbrx Biopharma Has Surged 483% This Year. But It Could Just Be Getting Started.The company has another update on its prostate cancer program that could further prod shares.
AMAM Twits
Here you can normally see the latest stock twits on AMAM, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
